Sarpogrelate, an antagonist of 5-HT2A receptor, treatment reduces restenosis after coronary stenting

被引：0
|
作者：
Fujita, M
Mizuno, K
Ho, M
Miwa, K
机构：
[1] Kyoto Univ, Coll Med Technol, Kyoto 606, Japan
[2] Nippon Med Coll, Chiba Hokusoh Hosp, Chiba, Japan
[3] Kawasaki Social Insurance Hosp, Kawasaki, Kanagawa, Japan
[4] Kansai Elect Power Hosp, Osaka, Japan
来源：
CIRCULATION | 2002年 / 106卷 / 19期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2927
引用
收藏
页码：592 / 592
页数：1
相关论文
共 50 条
  • [1] Sarpogrelate treatment reduces restenosis after coronary stenting
    Fujita, M
    Mizuno, K
    Ho, M
    Tsukahara, R
    Miyamoto, A
    Miki, O
    Ishii, K
    Miwa, K
    AMERICAN HEART JOURNAL, 2003, 145 (03)
  • [2] Antinociception in rat by sarpogrelate, a selective 5-HT2A receptor antagonist, is peripheral
    Obata, H
    Saito, S
    Ishizaki, K
    Goto, F
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 404 (1-2) : 95 - 102
  • [3] Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes
    Lee, D. -H.
    Lee, J. -E.
    Hur, J.
    Chun, E.
    Oh, T.
    Kim, K.
    Moon, J.
    Choi, S.
    Jang, H.
    Kim, H.
    Lim, S.
    DIABETOLOGIA, 2016, 59 : S514 - S514
  • [4] Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes
    Lee, Dong-Hwa
    Chun, Eun Ju
    Hur, Jee Hye
    Min, Se Hee
    Lee, Jie-Eun
    Oh, Tae Jung
    Kim, Kyoung Min
    Jang, Hak Chul
    Han, Seung Jin
    Kang, Doo Kyoung
    Kim, Hae Jin
    Lim, Soo
    ATHEROSCLEROSIS, 2017, 257 : 47 - 54
  • [5] Effects of the 5-HT2A receptor antagonist sarpogrelate in diabetic patients with complications -: A pilot study
    Hotta, N
    Nakamura, J
    Sumita, Y
    Yasuda, K
    Ito, M
    Takeuchi, T
    Hara, T
    Sakamoto, N
    CLINICAL DRUG INVESTIGATION, 1999, 18 (03) : 199 - 207
  • [6] Effects of the 5-HT2A Receptor Antagonist Sarpogrelate in Diabetic Patients with ComplicationsA Pilot Study
    Nigishi Hotta
    Jiro Nakamura
    Yasuhiro Sumita
    Keigo Yasuda
    Madoka Ito
    Toshihiko Takeuchi
    Tomohiro Hara
    Nobuo Sakamoto
    Clinical Drug Investigation, 1999, 18 : 199 - 207
  • [7] Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor
    Muntasir, Habib Abul
    Bhuiyan, Mohiuddin Ahmed
    Ishiguro, Masaji
    Ozaki, Masanobu
    Nagatomo, Takafumi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 102 (02) : 189 - 195
  • [8] The effects of the 5-HT2A receptor antagonist sarpogrelate hydrochloride on chronic hypoxic pulmonary hypertension in rats
    Geng, Jie
    Fan, Fen-ling
    He, Sai
    Liu, Ya
    Meng, Yan
    Tian, Hua
    Zhang, Dan
    Ma, Qiang
    Zhang, Jun-bo
    Tian, Hong-yan
    EXPERIMENTAL LUNG RESEARCH, 2016, 42 (04) : 190 - 198
  • [9] Sarpogrelate, a 5-HT2A Receptor Antagonist, Protects the Retina From Light-Induced Retinopathy
    Tullis, Brandon E.
    Ryals, Renee C.
    Coyner, Aaron S.
    Gale, Michael J.
    Nicholson, Alex
    Ku, Cristy
    Regis, Dain
    Sinha, Wrik
    Datta, Shreya
    Wen, Yuquan
    Yang, Paul
    Pennesi, Mark E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (08) : 4560 - 4569
  • [10] Sarpogrelate, a 5-HT2A receptor antagonist in intermittent claudication.: A Phase II European study
    Norgren, L.
    Jawien, A.
    Matyas, L.
    Rieger, H.
    Arita, K.
    VASCULAR MEDICINE, 2006, 11 (02) : 75 - 83
12345